Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: - Below 500,000 yuan: 27 individuals (39%) - 500,000-1,000,000 yuan: 29 individuals (42%) - 1,000,000-2,000,000 yuan: 10 individuals (15%) - 2,000,000-3,000,000 yuan: 2 individuals (3%) - Above 3,000,000 yuan: 1 individual (1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - The educational background indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu: 2.5587 million yuan - Cao Wei from Jichuan Pharmaceutical: 2.4107 million yuan - Yu Jie from Tianjin Tasly: 2.525 million yuan - Wu Rui from Yiling Pharmaceutical: 1.89 million yuan - Jiang Xianhong from Yibai Pharmaceutical: 1.3935 million yuan - Their tenure at the companies ranges from less than 1 year to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies: - Less than 10 meetings: 41 companies (59%) - 10-100 meetings: 17 companies (25%) - 100-300 meetings: 9 companies (13%) - 300-1000 meetings: 2 companies (3%) [7] - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical: 410 meetings - Qizheng Pharmaceutical: 404 meetings - Yunnan Baiyao: 298 meetings - Jinghua Pharmaceutical: 221 meetings - Pianzihuang: 207 meetings [9]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有69家上市中药公司，董事会秘书聘任总体情况如下（部分统计口 径剔除无效数据）。 从董秘的年龄分布来看，介于40-50岁的董秘是市场的中坚力量，占比达到42%；50岁以上的董秘占比 为29%；小于40岁的董秘群体占比为26%。其中，最年轻的上市公司董秘年仅32岁，为特一药业的许紫 兰。 从董秘的学历分布看，拥有大专、本科、硕士、博士学历的董秘占比分别为5%、42%、49%、4%，硕 士及以上学历董秘占比已超过半数。其中，获得博士学历的董秘仅三人，分别为以岭药业（维权）的吴 瑞、昆药集团的张梦珣、金花股份（维权）的张朝阳。 从薪酬分布看，A股中药上市公司董秘年薪平均值为74.24万元。经统计，处于50万以下、50万-100万、 100万-200万、200万-300万、300万以上各区间的人数分别为27 ...

分组1 - Watson Bio signed a strategic cooperation framework agreement with Yuxi State-owned Capital Operation Company to establish a long-term partnership in the vaccine and bioproducts industry [1] - The cooperation aims to promote innovation in vaccines and synthetic biological manufacturing through various methods such as establishing equity investment funds and strategic investments [1] - Watson Bio was founded in January 2001 and focuses on the research, production, and sales of human vaccines and biotechnological drugs [2] 分组2 - Yuan Dong Bio announced a preliminary transfer price of 42.06 yuan per share for its stock, attracting 12 institutional investors with a total subscription of 540,000 shares, resulting in a subscription multiple of 1.60 times [3] - Yuan Dong Bio was established in June 2009 and specializes in the research, production, and sales of chemical raw materials, high-end chemical drugs, and biological drugs [3] 分组3 - Weiming Environmental reported a total power generation of 2.262 billion kWh in the first half of the year, representing a year-on-year increase of 7.54% [4] - The company also achieved a total online power generation of 1.863 billion kWh, with an average online electricity price of 0.569 yuan per kWh [4] - Weiming Environmental was founded in December 2001 and focuses on low-carbon environmental technology, products, and services [5] 分组4 - Qidi Design won a bid for the Henan Airport Intelligent Computing Center project with a total bid amount of 860 million yuan [6] - The project includes construction, maintenance, and operation of a computing cluster, with a construction period of 150 calendar days [6] - Qidi Design was established in March 1988 and specializes in design consulting, construction engineering, and new energy projects [7] 分组5 - Tiantan Bio's subsidiary received approval for a production site change for its product "Recombinant Human Coagulation Factor VIII" used in treating hemophilia A [8] - The new production site is located in Chengdu, Sichuan Province [8] - Tiantan Bio was founded in June 1998 and focuses on blood products using human plasma and recombinant technology [9] 分组6 - East China Pharmaceutical's HDM1002 tablet clinical trial application was approved by the FDA, aimed at weight management for overweight or obese individuals [10] - The company also received approval for a new drug abbreviated application for injectable cabozantinib, enhancing its product pipeline in the anti-infection field [10] - East China Pharmaceutical was established in March 1993 and specializes in drug research, production, and sales [10] 分组7 - Jinlong Co. plans to acquire a 29.32% stake in Shenzhen Benmao Technology Co., Ltd. [11] - Jinlong Co. was founded in April 1997 and focuses on securities company operations [11] 分组8 - Hasi Lian's injectable diltiazem hydrochloride passed the consistency evaluation by the National Medical Products Administration [12] - The drug is primarily used for treating cardiovascular diseases [12] - Hasi Lian was established in June 1996 and specializes in the research, production, and sales of chemical drug formulations [13] 分组9 - Matrix Co. reported new signed orders of 272 million yuan in the second quarter, with a total of 677 million yuan in signed but uncompleted orders [14] - Matrix Co. was founded in March 2010 and focuses on space design and soft decoration [15] 分组10 - Nanshan Aluminum plans to use up to 1 billion yuan of idle funds for low-risk financial investments [16] - Nanshan Aluminum was established in March 1993 and specializes in the development, production, processing, and sales of aluminum and aluminum alloy products [17] 分组11 - Danhua Technology received a warning letter for failing to timely disclose related party transactions [18][19] - Danhua Technology was founded in February 1994 and focuses on the production and sales of coal chemical products [20] 分组12 - Jinkong Coal Industry announced a cash dividend of 0.755 yuan per share based on a total share capital of 1.674 billion shares [21] - Jinkong Coal Industry was established in July 2001 and specializes in coal production and sales [21] 分组13 - Blue Sky Gas announced that shareholders and the secretary of the board plan to reduce their holdings by a total of 2.61 million shares [22] - Blue Sky Gas was founded in December 2002 and focuses on pipeline natural gas and urban gas services [23] 分组14 - Huagong Technology received approval for the issuance of 2 billion yuan in short-term financing bonds and medium-term notes [24] - Huagong Technology was established in July 1999 and specializes in intelligent manufacturing equipment and related technologies [25] 分组15 - Chengjian Development completed the issuance of 500 million yuan in medium-term notes with a coupon rate of 2.05% [26] - Chengjian Development was founded in December 1998 and focuses on real estate development and investment [27] 分组16 - Feilong Co. reported a net profit of 210 million yuan in the first half of the year, a year-on-year increase of 14.49% [28] - The company achieved a total revenue of 2.162 billion yuan, a year-on-year decrease of 8.67% [28] - Feilong Co. was established in January 2011 and specializes in manufacturing thermal management components for automotive and civil applications [29] 分组17 - Guanghe Technology plans to invest 30 million yuan to establish a new venture capital fund focusing on emerging industries [30] - Guanghe Technology was founded in June 2002 and specializes in the research, production, and sales of multi-layer printed circuit boards [31] 分组18 - Dongnan Network won a bid for the EPC project of Qianjiang Century City Intelligent Comprehensive Science and Technology Park with a total bid amount of 1.183 billion yuan [32] - The project has a total construction area of 273,600 square meters and a planned total investment of 3.956 billion yuan [32] - Dongnan Network was established in December 2001 and focuses on steel structures and new energy [33] 分组19 - Guangdian Measurement plans to raise no more than 1.3 billion yuan through a private placement [34] - The funds will be used for various projects including testing platforms and upgrading laboratories [34] - Guangdian Measurement was founded in May 2002 and specializes in measurement services and technical services [35] 分组20 - Wanma Co. plans to invest in a project to produce 350,000 tons of environmentally friendly polymer materials [36] - The total investment for the project is approximately 1.245 billion yuan, with a construction period from 2025 to 2030 [36] - Wanma Co. was established in December 1996 and focuses on the research, production, and sales of wires, cables, and charging equipment [37] 分组21 - Dingxin Communications plans to sell its subsidiary Haina Smart for 240 million yuan [38] - Dingxin Communications was founded in March 2008 and specializes in low-voltage power line carrier communication products [39] 分组22 - Jiayun Technology plans to transfer its wholly-owned subsidiary Jinyuan Interactive for 10 million yuan [40] - Jiayun Technology was established in May 2002 and focuses on internet marketing services [41] 分组23 - Guangsheng Nonferrous plans to publicly transfer a 3% stake in Guangdong Pearl River Rare Earth Co., Ltd. [42] - The transfer price is not less than 5.9764 million yuan, aimed at clearing unrelated assets [42] - Guangsheng Nonferrous was founded in June 1993 and specializes in rare earth mining and processing [43] 分组24 - Zhongwei Semiconductor plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [44] - Zhongwei Semiconductor was established in June 2001 and focuses on the research, design, and sales of digital and analog chips [45] 分组25 - Zhongrong Co. announced that its chairman and general manager has been released from custody and is resuming normal duties [46] - Zhongrong Co. was founded in April 1990 and specializes in the research, design, production, and sales of paper packaging products [47] 分组26 - Jiangling Motors reported a net profit of 733 million yuan in the first half of the year, a year-on-year decrease of 18.17% [48] - The company achieved total revenue of 18.092 billion yuan, a year-on-year increase of 0.96% [48] - Jiangling Motors was established in January 1997 and focuses on the production and sales of commercial vehicles and related parts [49] 分组27 - Glodon plans to reduce its holdings by up to 2.08% of the company's shares [50] - Glodon was founded in August 1998 and specializes in digital construction platform services [51] 分组28 - Olin Bio's controlling shareholder plans to reduce its holdings by up to 3% of the company's shares [52] - Olin Bio was established in December 2009 and focuses on the research, production, and sales of human vaccines [53] 分组29 - Tianrun Industrial plans to acquire 100% of Shandong Altai's shares for 135 million yuan [54] - The acquisition aims to enhance the company's capabilities in lightweight automotive components [54] - Tianrun Industrial was founded in December 1995 and specializes in the production of crankshafts and connecting rods [55] 分组30 - Goer Technology plans to acquire Mega Precision Technology and Channel Well Industrial for approximately 10.4 billion HKD [56] - The acquisition aims to enhance Goer Technology's capabilities in precision components and smart hardware [56] - Goer Technology was established in June 2001 and focuses on precision components and intelligent acoustic products [57]

证券代码：002349 证券简称：精华制药 公告编号：2025-028 精华制药集团股份有限公司 关于孙公司获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 申请事项：境内生产化学原料药上市申请 登记号：Y20230001302 受理号：CYHS2460104 化学原料药名称：通用名称：利托那韦 英文名/拉丁名：Ritonavir 化学原料药注册标准编号：YBY67042025 一、原料药基本情况 有效期：18 个月 近日，精华制药集团股份有限公司（以下简称"公司"）孙公司精华制药 集团南通有限公司（以下简称"南通公司"）获得国家药品监督管理局核准签 发的利托那韦《化学原料药上市申请批准通知书》，现就相关情况公告如下： 通知书编号：2025YS00593 包装规格：1kg/袋；2kg/袋；5kg/袋；10kg/袋； 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 生产企业：精华制药集团南通有限公司 地址：如东沿海经济开发区海滨三 ...

Group 1 - The company, Jinghua Pharmaceutical Group Co., Ltd., is involved in a legal case where its subsidiary, Ningxia Senxuan Pharmaceutical Co., Ltd., is the defendant in a lawsuit initiated by Yinchuan Railway Transportation Procuratorate [1][2] - The lawsuit concerns the illegal disposal of approximately 150 tons of toxic waste, resulting in damages amounting to 857,897.97 yuan [2] - The company holds a 72.31% stake in Senxuan Pharmaceutical, which in turn owns 51% of Ningxia Senxuan, indicating a significant ownership structure that may influence the company's financials [3] Group 2 - As of the announcement date, there are no other significant lawsuits or arbitration matters involving the company or its subsidiaries that require disclosure [3] - The potential impact of the lawsuit on the company's current and future profits is considered minimal, as the lawsuit amount is small and is not expected to significantly affect the company's net profit for 2025 [3]

1、案件所处的诉讼阶段：法院已受理，尚未开庭； 证券代码：002349 证券简称：精华制药 公告编号：2025-027 精华制药集团股份有限公司 关于孙公司涉及诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 特别提示： 2、上市公司所处的当事人地位：精华制药集团股份有限公司（以下简称 "公司"）孙公司宁夏森萱药业有限公司（以下简称"宁夏森萱"）为本次案 件被告； 3、涉案的金额：40-60万元（存在不确定性）； 4、对上市公司损益产生的影响：本次诉讼尚未开庭审理，对本期利润及期 后利润的影响尚不确定。敬请广大投资者关注公司在指定信息披露媒体上披露 的相关公告，理性投资，注意投资风险。 一、 本次诉讼事项受理的基本情况 公司于近日收到江苏森萱医药股份有限公司（以下简称"森萱医药"）转 发的关于宁夏森萱的《起诉书》（宁银铁检刑诉〔2025〕22号）、《量刑建议 书》（宁银铁检量建〔2025〕24号）。截至本公告披露日，本案尚未开庭。 二、本诉讼事项的基本情况 （一） （原告/上诉人）基本信息： 姓名或名称：银川铁路运输检察院 法定代表人/法定代理人/ ...

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of 0.785060 RMB per 10 shares, following an increase in total shares due to the issuance of restricted stock [2][5]. Summary by Sections Share Capital and Dividend Distribution - The company completed the registration of 15,494,000 new shares, increasing the total share capital from 814,180,908 shares to 829,674,908 shares [2][3]. - The cash dividend for 2024 is set at 0.785060 RMB per 10 shares, with a total cash distribution amounting to approximately 65.13 million RMB [2][5]. Adjustments to Dividend Distribution - The cash dividend distribution will be adjusted based on the new total share capital, ensuring that the total cash dividend remains unchanged [3][5]. - The adjusted cash dividend per share is calculated to be approximately 0.078506 RMB after the increase in total shares [3]. Key Dates - The record date for the dividend distribution is set for June 5, 2025, and the ex-dividend date is June 6, 2025 [6]. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their securities companies on the ex-dividend date [8]. Consultation and Documentation - The company has provided contact information for inquiries and has listed documents available for review regarding the dividend distribution [10].

证券代码：002349 证券简称：精华制药 公告编号：2025-026 精华制药集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 特别提示： 2025年5月22日，公司在中国证券登记结算有限责任公司深圳分公司办理完 毕首期限制性股票的登记手续，公司新增股份15,494,000股，公司股本总数由 814,180,908股增加至829,674,908股，按照"现金分红总额固定不变"的原 则，公司2024年年度权益分派方案为：以公司现有总股本829,674,908股为基 数，向可参与权益分派的全体股东每10股派0.785060元人民币现金（含税）， 不送红股，不以公积金转增股本。本次实际派发现金分红总额=可参与权益分派 股份总数×（每 10 股派息金额÷10）=829,674,908×（0.785060÷10）= 65,134,458.32元（含税），实际现金分红总额与拟分配现金总额略有差异主要 系每10股现金分红金额保留六位小数所致，实际分派结果以中国证券登记结算 有限责任公司深圳分公司（以下简称"中国结算深圳分 ...

证券代码：002349 证券简称：精华制药 公告编号：2025-025 精华制药集团股份有限公司 关于 2025 年限制性股票激励计划 首次授予登记完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 根据中国证监会《上市公司股权激励管理办法》、深圳证券交易所、中国证 券登记结算有限责任公司深圳分公司有关规则的规定，精华制药集团股份有限公 司（以下简称"公司"）完成了 2025 年限制性股票激励计划的首次授予登记工 作，具体情况公告如下： 一、本期激励计划已履行的相关审批程序 四次会议，审议通过了《2025年限制性股票激励计划（草案）》《2025年限制性 股票激励计划实施考核管理办法》以及《关于提请股东会授权董事会办理公司 的相关事项进行核实并出具了相关核查意见。 的姓名和职务在公司内部进行了公示，截至公示期满，对公示名单人员没有任何 组织或个人对激励对象名单提出异议。有个别员工建议扩大激励对象范围。2025 年4月28日，公司披露了《监事会关于2025年限制性股票激励计划激励对象名单 证券代码：002349 证券简称：精华制药 公告编 ...

证券代码：002349 证券简称：精华制药 公告编号：2025-025 精华制药集团股份有限公司 关于 2025 年限制性股票激励计划 首次授予登记完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 1、首次授予日：2025 年 5 月 8 日 2、首次授予的限制性股票上市日：2025 年 5 月 22 日 3、首次授予登记人数：105 人 4、首次授予数量：1,549.40 万股 5、首次授予价格：3.66 元/股 6、股票来源：公司向激励对象定向发行公司 A 股普通股股票 根据中国证监会《上市公司股权激励管理办法》、深圳证券交易所、中国证 券登记结算有限责任公司深圳分公司有关规则的规定，精华制药集团股份有限公 司（以下简称"公司"）完成了 2025 年限制性股票激励计划的首次授予登记工 作，具体情况公告如下： 一、本期激励计划已履行的相关审批程序 1、2025年4月11日，公司召开的第六届董事会第五次会议和第六届监事会第 四次会议，审议通过了《2025年限制性股票激励计划（草案）》《2025年限制性 股票激励计划实施考核管理办法》 ...